CEO Dr Deborah O’Neil and the NovaBiotics team will be attending the BIO CEO & Investor Conference, hosted by the Biotechnology Innovation Organization on the 16th-18th February 2021. Meet with us through the event portal BIO CEO & Investor Event to learn more about our financing plans and strategy for our exciting pipeline of first-in-class antimicrobial and respiratory product candidates including Nylexa for Covid-19.
- NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia
- NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy
- NovaBiotics attending the BIO Digital Meeting, June 2021
- Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news
- Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics